Revenue
2017
2018
2019
2020
2021
2023
2024
2025
KIORA PHARMACEUTICALS INC (KPRX)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $16.0M | $0 | — | $0 | $12,059 | $2.7M | $1.7M | $407,518 | $669,259 | $0 | — |
| Research & development | $10.8M | $7.8M | $4.0M | $3.4M | $5.4M | $3.6M | $5.4M | $8.1M | $10.3M | $8.4M | $2.7M | $531,116 |
| Operating expenses | $12.8M | $11.5M | $12.6M | $12.3M | $14.2M | $6.9M | $9.8M | $12.5M | $15.0M | $14.0M | $6.7M | $2.5M |
| Operating income | −$12.8M | $4.5M | −$12.6M | −$12.3M | −$14.2M | −$6.9M | — | −$10.8M | — | — | — | — |
| EBITDAderived | −$12.8M | $4.5M | −$12.5M | −$12.3M | −$14.2M | −$6.8M | — | −$10.8M | — | — | — | — |
| Net income | −$10.8M | $3.6M | −$12.5M | −$13.6M | −$13.8M | −$6.9M | −$7.1M | −$10.8M | −$13.2M | −$13.3M | −$8.4M | −$1.6M |
| Basic EPSper diluted share | -$2.60 | $0.93 | -$24.25 | -$18.55 | -$57.12 | -$1.49 | -$2.23 | -$4.57 | -$0.93 | -$1.51 | -$2.70 | -$9.20 |
| Diluted EPSper diluted share | -$2.64 | $0.87 | -$24.25 | -$18.55 | -$57.12 | -$1.49 | -$2.23 | -$4.57 | -$0.93 | -$1.51 | -$2.70 | -$9.20 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Sep 11, 2024Form 4 | Stengone Carmine N.Director | BuyCommon Stock | 1.3K | $3.68 | $4.6K | 1.3K |
| Sep 10, 2024Form 4 | Shapiro AronDirector | BuyCommon Stock · indirect | 3.0K | $3.60 | $10.8K | 3.0K |
| Aug 19, 2024Form 4 | Walters-Hoffert LisaDirector | BuyCommon Stock | 1.3K | $3.86 | $4.8K | 1.3K |
| Aug 19, 2024Form 4 | TYLE PRAVEENDirector | BuyCommon Stock | 5.0K | $3.96 | $19.8K | 5.0K |
| Aug 14, 2024Form 4 | Tosca MelissaCFO | BuyCommon Stock | 2.0K | $3.21 | $6.4K | 13.6K |